Novotech conducts multinational study for THVD-201 in Korea

Published: 2011-08-31 06:58:00

Updated: 2011-08-31 06:58:00

The U.S.-based TheraVida, Inc., a privately-held California biopharmaceutical company, has announced the start of a Phase 2 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) in Korea, Australia and New Zealand, according to Novotech.

Novotech, a leading Asia Pacific contract research organization, has been ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.